Steve Silver
Recent Quotes
"PMN expects to file an NDA for PMN310 with the FDA by 2022E."
—
Steve Silver, Argus Research
(10/28/22)
more >
"PMN designated PMN267 as its lead candidate for treatment of ALS."
—
Steve Silver, Argus Research
(7/6/22)
more >
"PMN's PMN310 potentially represents a best-in-class opportunity."
—
Steve Silver, Argus Research
(6/27/22)
more >
"We view PMN's path to clinical value inflection favorably."
—
Steve Silver, Argus Research
(4/13/22)
more >
Due to permission requirements, not all quotes are shown.
